BioNexus Gene Lab Corp. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 10.93 million compared to USD 13.36 million a year ago.

Net loss was USD 0.355966 million compared to net income of USD 0.751571 million a year ago. Basic loss per share from continuing operations was USD 0.024 compared to basic earnings per share from continuing operations of USD 0.048 a year ago.